Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on TScan Therapeutics (NASDAQ:TCRX) and maintained a $10 price target.
August 13, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating on TScan Therapeutics and maintained a $10 price target.
The reiteration of an Outperform rating and the maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100